Direxion mRNA ETF
MSGR
MSGR was delisted on the 21st of April, 2023.
3 hedge funds and large institutions have $1.03M invested in Direxion mRNA ETF in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
23% less capital invested
Capital invested by funds: $1.33M → $1.03M (-$303K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $353K | +$15.3K | +1,057 | +4% |
|
2
Bank of America
Charlotte,
North Carolina
| $338K | – | – | – |
|
3
Citigroup
New York
| $338K | – | – | – |
|
MSGR Hedge Fund Activity: Q2 2022 in Review
3 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q2 2022, worth a combined $1.03M — down 23% from $1.33M a quarter earlier.
Fund positioning in MSGR was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $15.3K.
- 3 institutional investors held Direxion mRNA ETF (MSGR) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.03M of Direxion mRNA ETF stock for Q2 2022, down 23% quarter-over-quarter.
- 0 funds opened new Direxion mRNA ETF positions in Q2 2022 and 0 closed out.
- The largest Direxion mRNA ETF buyer in Q2 2022 was UBS Group, an estimated $15.3K added.
Based on aggregated 13F filings for Q2 2022.